文献速递免疫规划

新型腺病毒编码病毒样颗粒展示胎盘疟疾相关VAR2CSA抗原

Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen.
PubMed 文献 · Vaccine · 2017-01-25

本研究设计腺病毒编码的病毒样颗粒(VLP),共编码SIV gag与VAR2CSA,并将VAR2CSA融合至MMTV包膜蛋白或甲型流感血凝素的跨膜及胞质尾区。在Balb/c小鼠中,以HA TM-CT融合的VAR2CSA初次免疫后诱导ID1-ID2a特异性抗体显著优于其他设计。序贯研究显示,以VLP疫苗初次免疫、蛋白加强可诱导更高抗体应答并增强抑制寄生虫结合CSA,优于蛋白初次-双加强方案。

要点

  • 腺病毒VLP共编码SIV gag与VAR2CSA,三种设计比较VLP锚定对免疫原性的影响。
  • HA TM-CT融合的VAR2CSA初次免疫后诱导ID1-ID2a特异性抗体显著优于其他设计。
  • VLP初次-蛋白双加强较蛋白初次-双加强诱导更高抗体并增强抑制寄生虫结合CSA。

核心结论

  • 修饰VLP锚定是病毒编码逆转录病毒VLP疫苗的重要优化点。
  • 腺病毒VLP经重组蛋白加强有希望提高保护性VAR2CSA特异性抗体水平。

研究设计与样本

  • 设计三种腺病毒编码VLP:VAR2CSA融合MMTV TM-CT、融合HA TM-CT、无TM-CT的非VLP对照。
  • 在Balb/c小鼠中进行初次免疫原性研究,并开展序贯研究比较可溶性VAR2CSA蛋白疫苗(已进入I期临床试验NCT02647489)。

主要发现

  • 初次免疫后,HA TM-CT融合的VAR2CSA诱导ID1-ID2a特异性抗体显著优于其他设计。
  • 以VAR2CSA HA TM-CT或VAR2CSA MMTV TM-CT作为初次疫苗进行蛋白双加强,诱导的抗体应答和抑制寄生虫结合CSA的能力均高于蛋白初次-双加强方案。
  • 肽阵列分析混合血清显示,以VAR2CSA HA TM-CT初次免疫的小鼠独特靶向多个表位。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The malaria parasite Plasmodium falciparum presents antigens on the infected erythrocyte surface that bind human receptors expressed on the vascular endothelium. The VAR2CSA mediated binding to a distinct chondroitin sulphate A (CSA) is a crucial step in the pathophysiology of placental malaria and the CSA binding region of VAR2CSA has been identified as a promising vaccine target against placental malaria. Here we designed adenovirus encoded virus-like particles (VLP) by co-encoding Simian Immunodeficiency Virus (SIV) gag and VAR2CSA. The VAR2CSA antigen was fused to the transmembrane (TM) and cytoplasmic tail (CT) domains of either the envelope protein of mouse mammary tumour virus (MMTV) or the hemagglutinin (HA) of influenza A. For a non-VLP incorporation control, a third design was made where VAR2CSA was expressed without TM-CT domains. In the primary immunogenicity study in Balb/c mice, VAR2CSA fused to HA TM-CT was significantly superior in inducing ID1-ID2a specific antibodies after the first immunization. A sequential study was performed to include a comparison to the soluble VAR2CSA protein vaccine, which has entered a phase I clinical trial (NCT02647489). The results revealed the induction of higher antibody responses and increased inhibition of parasite binding to CSA using either VAR2CSA HA TM-CT or VAR2CSA MMTV TM-CT as priming vaccines for protein double-boost immunizations, compared to protein prime-double boost regimen. Analysis of pooled serum samples on peptide arrays revealed a unique targeting of several epitopes in mice that had been primed with VAR2CSA HA TM-CT. Consequently, modification of VLP anchors is an important point of optimization in virus-encoded retroviral VLP-based vaccines, and adenovirus VLPs boosted by recombinant proteins offer hope of increasing the levels of protective VAR2CSA specific antibodies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Andersson AC, Resende M, Salanti A, et al. Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen. Vaccine. 2017. PMID: 28131394. doi:10.1016/j.vaccine.2017.01.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。